Hyperliquid Strategies Inc., which trades on Nasdaq under the ticker PURR, filed an amended Form S-1 on July 21, 2026 registering the resale of up to 35,156,660 shares of common stock held by a single selling securityholder, Rorschach Advisors LLC. The registered block consists of 7,761,860 shares already issued and 27,394,800 shares issuable on exercise of warrants struck at $9.375, $12.50 and $18.75. Together the position represents roughly 15.4% of shares outstanding.

The distinction matters for how the filing should be read. A resale registration does not raise money for the issuer. It makes an existing holder's shares freely tradable, and any proceeds from sales under the prospectus go to the selling securityholder rather than to the company. What the registration does supply is a disclosure refresh, and this one arrives with a treasury program that has moved faster than almost any comparable corporate token strategy on record.

A $1 billion equity facility drawn in a single quarter

The company is the surviving public entity from the Sonnet BioTherapeutics de-SPAC that closed on December 2, 2025. Since then it has funded a digital-asset treasury through a committed equity facility with Chardan sized at up to $1 billion. The amended prospectus quantifies how much of that capacity has already been consumed, and the pace is the story.

From the Commencement Date through July 15, 2026, the Company has issued approximately 76.1 million shares of Common Stock, generating net proceeds of approximately $647 million that was primarily used to purchase HYPE tokens. Approximately 75.8 million of those shares have been issued since March 31, 2026, generating net proceeds of approximately $645 million since that date. — Hyperliquid Strategies Inc., Form S-1/A, filed July 21, 2026

Read against the calendar, those two sentences describe a program that went from standing start to near-full deployment inside roughly one quarter. Of the approximately 76.1 million shares issued through July 15, 2026, approximately 75.8 million came after March 31, 2026, and approximately $645 million of the approximately $647 million in net proceeds was raised in that same post-quarter window. Financial statements dated as of March 31 therefore capture only a small fraction of the share count and cash flow the company is now operating with, which is precisely why the prospectus carries the July 15 update as a subsequent-events style disclosure.

The proceeds went into HYPE, the native token of the Hyperliquid protocol. The company states it held approximately 29.3 million HYPE tokens as of July 15, 2026, up from the 12.5 million tokens on the balance sheet at the closing of the business combination, and says it believes that position is the largest HYPE holding of any U.S. public company. The treasury has therefore more than doubled in token terms since December, funded almost entirely with newly issued equity rather than operating cash or debt.

The $169.2 million line that is not an operating loss

The most conspicuous number in the financial statements is a $169.2 million loss on HYPE contribution commitment recognized at the December 2025 closing. The mechanics are narrow and worth stating precisely: 12.5 million tokens were committed to the transaction at a reference price of $46.372, and the tokens were valued at $411.3 million when they were actually delivered against $580.5 million at the time the commitment was struck. The charge is the mark on that gap. It is not an operating loss, it does not reflect trading activity by the company, and it says nothing about how the underlying business performed. It is the accounting consequence of a fixed-price token commitment settling into a lower market.

Against that charge, the filing reports a $105.2 million unrealized gain on digital assets for the nine months ended March 31, 2026. The two figures move in opposite directions and derive from different events, and the company presents them separately rather than as a netted result. For readers building a picture of the entity's economics, the takeaway is that reported results are dominated by mark-to-market movement on a single token rather than by revenue-producing operations, and that the sign of any given period's result is largely a function of where HYPE happened to be marked on the closing date.

The warrant component of the registered block carries its own caveat, and the filing supplies it. The 27,394,800 warrant shares would nominally correspond to $371.0 million in aggregate exercise proceeds if every warrant were exercised for cash at its stated strike. The prospectus states that cashless exercise makes that gross figure unlikely to materialize, and that the company would likely receive approximately zero from the warrants in practice. Treating the $371.0 million as pending cash inflow would misread the disclosure; the realistic base case in the document is that the warrants dilute without funding.

What the registration adds to the market picture is supply visibility. Roughly 15.4% of the share count becomes eligible for resale under a prospectus, on top of an equity facility that has already issued 76.1 million shares in months. The document discloses the size and timing of that potential supply rather than predicting how it will be used, and Rorschach Advisors retains discretion over whether and when to sell. Registration is a permission, not a commitment to trade.

One caution on how the filing is being read elsewhere: the amendment does not disclose a material weakness in internal control over financial reporting. The document contains standard forward-looking risk-factor language of the form describing what could follow if deficiencies were identified in the future, which is boilerplate common to newly public de-SPAC issuers and is not a statement that a control failure has occurred. Anyone screening the filing on keyword matches should check the surrounding sentence before recording it as a control event.

The near-term disclosure items to watch are mechanical. The remaining headroom under the $1 billion Chardan facility is now modest relative to what has been drawn, so the next periodic report should show either a materially slower issuance pace or an expanded or replacement funding arrangement. The first financial statements to fully incorporate the post-March issuance will restate the scale of the balance sheet, and the treatment of HYPE marks in that period will determine how much of the token's movement flows through reported results. Each of those is a filing question with a filing answer.